Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(5-6):759–763. doi: 10.1038/sj.bjc.6690122

Identification of a C/G polymorphism in the promoter region of the BRCA1 gene and its use as a marker for rapid detection of promoter deletions

A Catteau 1, C-F Xu 1, M A Brown 1, S Hodgson 1, J Greenman 1, C G Mathew 1, A M Dunning 1, E Solomon 1
PMCID: PMC2362680  PMID: 10070866

Abstract

Reduced expression of BRCA1 has been implicated in sporadic breast cancer, although the mechanisms underlying this phenomenon remain unclear. To determine whether regulatory mutations could account for the reduced expression, we screened the promoter region by sequencing in 20 patients with sporadic disease. No mutations were detected; however, a new polymorphism consisting of a C-to-G base change within the β-promoter was identified, with the frequency of the G allele being 0.34. Close to complete linkage disequilibrium was found between this marker and the Pro871Leu polymorphism, situated in exon 11, which has previously been shown not to be associated with breast or ovarian cancer. This indicates that the C/G polymorphism is also unlikely to play a role in either disease. However, the strength of linkage disequilibrium between these markers permitted their use for rapid screening for genomic deletions within BRCA1. A series of 214 cases with familial breast cancer were analysed using this approach; 88/214 were heterozygous for the promoter polymorphism, thereby excluding a deletion in this region. Among the remaining patients, one hemizygous case reflecting a promoter deletion was successfully identified. Therefore, this study indicates that deletions within the β-promoter region of BRCA1 are an uncommon event in familial breast cancer. Furthermore, it suggests that mutations within the BRCA1 promoter are unlikely to account for the reported decreased expression of BRCA1 in sporadic disease. 1999 Cancer Research Campaign

Keywords: breast cancer, BRCA1 promoter, C/G polymorphism, linkage disequilibrium, deletion marker

Full Text

The Full Text of this article is available as a PDF (100.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambrosone C. B., Freudenheim J. L., Marshall J. R., Graham S., Vena J. E., Brasure J. R., Michalek A. M., Laughlin R., Nemoto T., Shields P. G. The association of polymorphic N-acetyltransferase (NAT2) with breast cancer risk. Ann N Y Acad Sci. 1995 Sep 30;768:250–252. doi: 10.1111/j.1749-6632.1995.tb12132.x. [DOI] [PubMed] [Google Scholar]
  2. Brown M. A., Xu C. F., Nicolai H., Griffiths B., Chambers J. A., Black D., Solomon E. The 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21. Oncogene. 1996 Jun 20;12(12):2507–2513. [PubMed] [Google Scholar]
  3. Chakravarti A., Buetow K. H., Antonarakis S. E., Waber P. G., Boehm C. D., Kazazian H. H. Nonuniform recombination within the human beta-globin gene cluster. Am J Hum Genet. 1984 Nov;36(6):1239–1258. [PMC free article] [PubMed] [Google Scholar]
  4. Couch F. J., Weber B. L. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat. 1996;8(1):8–18. doi: 10.1002/humu.1380080102. [DOI] [PubMed] [Google Scholar]
  5. Dobrovic A., Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 1997 Aug 15;57(16):3347–3350. [PubMed] [Google Scholar]
  6. Dunning A. M., Chiano M., Smith N. R., Dearden J., Gore M., Oakes S., Wilson C., Stratton M., Peto J., Easton D. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet. 1997 Feb;6(2):285–289. doi: 10.1093/hmg/6.2.285. [DOI] [PubMed] [Google Scholar]
  7. Feigelson H. S., Coetzee G. A., Kolonel L. N., Ross R. K., Henderson B. E. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 1997 Mar 15;57(6):1063–1065. [PubMed] [Google Scholar]
  8. Ford D., Easton D. F., Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995 Dec;57(6):1457–1462. [PMC free article] [PubMed] [Google Scholar]
  9. Futreal P. A., Liu Q., Shattuck-Eidens D., Cochran C., Harshman K., Tavtigian S., Bennett L. M., Haugen-Strano A., Swensen J., Miki Y. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994 Oct 7;266(5182):120–122. doi: 10.1126/science.7939630. [DOI] [PubMed] [Google Scholar]
  10. Hosking L., Trowsdale J., Nicolai H., Solomon E., Foulkes W., Stamp G., Signer E., Jeffreys A. A somatic BRCA1 mutation in an ovarian tumour. Nat Genet. 1995 Apr;9(4):343–344. doi: 10.1038/ng0495-343. [DOI] [PubMed] [Google Scholar]
  11. Krontiris T. G., Devlin B., Karp D. D., Robert N. J., Risch N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med. 1993 Aug 19;329(8):517–523. doi: 10.1056/NEJM199308193290801. [DOI] [PubMed] [Google Scholar]
  12. Mancini D. N., Rodenhiser D. I., Ainsworth P. J., O'Malley F. P., Singh S. M., Xing W., Archer T. K. CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene. 1998 Mar 5;16(9):1161–1169. doi: 10.1038/sj.onc.1201630. [DOI] [PubMed] [Google Scholar]
  13. Merajver S. D., Pham T. M., Caduff R. F., Chen M., Poy E. L., Cooney K. A., Weber B. L., Collins F. S., Johnston C., Frank T. S. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet. 1995 Apr;9(4):439–443. doi: 10.1038/ng0495-439. [DOI] [PubMed] [Google Scholar]
  14. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  15. Petrij-Bosch A., Peelen T., van Vliet M., van Eijk R., Olmer R., Drüsedau M., Hogervorst F. B., Hageman S., Arts P. J., Ligtenberg M. J. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997 Nov;17(3):341–345. doi: 10.1038/ng1197-341. [DOI] [PubMed] [Google Scholar]
  16. Puget N., Torchard D., Serova-Sinilnikova O. M., Lynch H. T., Feunteun J., Lenoir G. M., Mazoyer S. A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res. 1997 Mar 1;57(5):828–831. [PubMed] [Google Scholar]
  17. Smith T. M., Lee M. K., Szabo C. I., Jerome N., McEuen M., Taylor M., Hood L., King M. C. Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res. 1996 Nov;6(11):1029–1049. doi: 10.1101/gr.6.11.1029. [DOI] [PubMed] [Google Scholar]
  18. Swensen J., Hoffman M., Skolnick M. H., Neuhausen S. L. Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family. Hum Mol Genet. 1997 Sep;6(9):1513–1517. doi: 10.1093/hmg/6.9.1513. [DOI] [PubMed] [Google Scholar]
  19. Thompson M. E., Jensen R. A., Obermiller P. S., Page D. L., Holt J. T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet. 1995 Apr;9(4):444–450. doi: 10.1038/ng0495-444. [DOI] [PubMed] [Google Scholar]
  20. Xu C. F., Brown M. A., Chambers J. A., Griffiths B., Nicolai H., Solomon E. Distinct transcription start sites generate two forms of BRCA1 mRNA. Hum Mol Genet. 1995 Dec;4(12):2259–2264. doi: 10.1093/hmg/4.12.2259. [DOI] [PubMed] [Google Scholar]
  21. Xu C. F., Chambers J. A., Solomon E. Complex regulation of the BRCA1 gene. J Biol Chem. 1997 Aug 22;272(34):20994–20997. doi: 10.1074/jbc.272.34.20994. [DOI] [PubMed] [Google Scholar]
  22. Xu C. F., Solomon E. Mutations of the BRCA1 gene in human cancer. Semin Cancer Biol. 1996 Feb;7(1):33–40. doi: 10.1006/scbi.1996.0005. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES